Mazdutide

Batch #425912Batch # 425912
Report #11196Report # 11196
Tested at99.92% PurityTested at 99.92% Purity
Size: 10mg
Money Back Guarantee Money Back Guarantee
Satisfaction Guarantee Satisfaction Guarantee
Easy Returns Easy Returns
Secure Ordering Secure Ordering
2-Day Shipping 2-Day Shipping
Third Party Tested Third Party Tested
Batch & Lot Tracking Batch & Lot Tracking

RESEARCH USE ONLY
These compounds are NOT intended for human consumption, clinical use, or veterinary applications. We are not affiliated with any pharmaceutical companies or their commercial medications. By placing an order, you certify these materials will be used exclusively for in vitro testing and laboratory experimentation only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.

About Mazdutide

Mazdutide is an investigational peptide studied at the bench for receptor pharmacology, analytical method development, and in-vitro characterization. This material is supplied for research use only and is not approved for any medical use.

Form

Lyophilized powder in 3 mL glass vial

Application

Research peptide for studies of dual GLP-1 receptor / glucagon receptor (GLP-1R/GCGR) agonism in metabolic biology 

Appearance

Solid, white to off-white lyophilized powder

Chemical Formula

C₂₁₀H₃₂₂N₄₆O₆₇  

PubChem CID

167312357

CAS Number

2259884-03-0

Molecular Weight

≈ 4,563.1 g/mol 

Synonyms

IBI-362; IBI362; LY-3305677; LY3305677

Storage

Keep sealed, protected from light and moisture. Lyophilized: ≤ −20 °C for long-term (or 2–8 °C short-term). After reconstitution: 2–8 °C; avoid repeated freeze–thaw; use sterile technique in research workflows.

1. Overview 

Mazdutide (also known as IBI362 or LY3305677) is a once-weekly dual-agonist peptide that targets both the GLP-1 receptor and the glucagon receptor. It is being developed to help with obesity, weight control, and type-2 diabetes by reducing body fat, lowering blood sugar, and improving related metabolic markers. PubMed+1

It is currently being tested in China with several Phase II and Phase III clinical trials involving participants with obesity, type 2 diabetes, and metabolic dysfunction. Early studies have shown promising results in reducing body weight and improving glycemic control, with consistent tolerability across different doses. Ongoing research aims to evaluate long-term safety, cardiovascular outcomes, and the peptide’s effectiveness in broader patient populations.

 

2. Human Clinical Findings 

One important study was a Phase II randomized controlled trial in Chinese overweight or obese adults. Participants (n = 248) were assigned to different once-weekly doses of mazdutide (3 mg, 4.5 mg, or 6 mg) or placebo for 24 weeks. The result: mazdutide produced weight loss of –6.7 %, –10.4 %, and –11.3 % for the 3 mg, 4.5 mg, and 6 mg doses respectively, versus a small gain in the placebo group. The drug was well tolerated, with common side effects including nausea, diarrhea, and respiratory-infection symptoms. PubMed

Another trial, called DREAMS-1, focused on Chinese adults with type 2 diabetes inadequately controlled by diet and exercise alone. In doses of 4 mg and 6 mg for 24 weeks, mazdutide delivered significant reductions in HbA1c and improved percentages of participants achieving optimal blood-sugar control compared to placebo. BioSpace

A more recent head-to-head Phase III study (DREAMS-3) compared mazdutide 6 mg once a week to semaglutide 1 mg in Chinese adults with type-2 diabetes and obesity. In that study (349 participants), 48.0 % of mazdutide users achieved the target (HbA1c < 7.0 % and ≥ 10 % body-weight loss), compared to 21.0 % in the semaglutide group. Average body-weight reduction was ~10.29 % for mazdutide vs 6.0 % for semaglutide at week 32.

 

3. Safety & Considerations  

Mazdutide was generally well tolerated in trials up to 24 weeks and beyond. The common side effects were mostly gastrointestinal – such as nausea, diarrhea – and some increase in heart rate at higher doses, but no major safety signals have been reported in published Phase II / III data. 

Because it acts on both GLP-1 and glucagon receptors, developers monitor metabolic and cardiovascular markers carefully, especially in long-term trials. To date, the safety profile looks acceptable for the doses studied, but longer term data and broader populations (beyond China) are still pending. 

 

4. Summary 

Mazdutide is a promising new peptide-based medicine for obesity and type-2 diabetes, particularly in Chinese populations. Its once-weekly dosing produced meaningful weight loss (8-12 %) in mid-term trials, improved blood sugar control, and was mostly well tolerated. It may have advantages over semaglutide in certain comparisons, but as with any active drug, ongoing monitoring and further Phase III results will determine how it fits into clinical practice.

References

  1. Phase 2 RCT of mazdutide in Chinese overweight or obese adults. PubMed. PubMed 

  2. DREAMS-1 clinical results at ADA 2025. BioSpace 

  3. DREAMS-3 head-to-head vs semaglutide (Phase III). BioSpace+1 

  4. Systematic review & meta-analysis of mazdutide’s weight-loss effects. Frontiers

 

You ask,
we answer.